世界のヒト胚性幹細胞の市場規模は2023年に20億2000万ドルと評価され、2024年から2030年にかけて10.5%のCAGRで成長すると予測されています。幹細胞の需要は、主に慢性疾患や悪性疾患の有病率の上昇により高くなっています。再生医療と幹細胞治療に関する継続的な研究が、加齢性疾患の再生治療の需要を促しています。悪性腫瘍を治療するためのがん研究と幹細胞治療に対する政府の支援が、市場の状況にプラスの影響を与えます。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Human Embryonic Stem Cells Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Human Embryonic Stem Cells Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social Landscape
3.4.2.3. Technological Landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape
Chapter 4. Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Human Embryonic Stem Cells Market: Application Movement Analysis, 2023 & 2030 (USD Million)
4.3. Regenerative Medicine
4.3.1. Regenerative Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Stem Cell Biology Research
4.4.1. Stem Cell Biology Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Tissue Engineering
4.5.1. Tissue Engineering Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Toxicology Testing
4.6.1. Toxicology Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Human Embryonic Stem Cells Market: Regional Estimates & Trend Analysis
5.1. Human Embryonic Stem Cells Market Share, By Region, 2023 & 2030 (USD Million)
5.2. North America
5.2.1. North America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. U.S.
5.2.2.1. U.S. Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.3. Canada
5.2.3.1. Canada Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.4. Mexico
5.2.4.1. Mexico Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3. Europe
5.3.1. Europe Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. UK
5.3.2.1. UK Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Germany
5.3.3.1. Germany Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.4. France
5.3.4.1. France Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.5. Italy
5.3.5.1. Italy Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.6. Spain
5.3.6.1. Spain Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.7. Denmark
5.3.7.1. Denmark Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.8. Sweden
5.3.8.1. Sweden Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.9. Norway
5.3.9.1. Norway Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Asia Pacific
5.4.1. Asia Pacific Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. China
5.4.2.1. China Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. Japan
5.4.3.1. Japan Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.4. India
5.4.4.1. India Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.5. South Korea
5.4.5.1. South Korea Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.6. Australia
5.4.6.1. Australia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Latin America
5.5.1. Latin America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Brazil
5.5.2.1. Brazil Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Middle East and Africa
5.6.1. Middle East and Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.2. Saudi Arabia
5.6.2.1. Saudi Arabia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.3. UAE
5.6.3.1. UAE Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.4. South Africa
5.6.4.1. South Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis by Key Market Participants
6.2. Company Categorization
6.3. Company Heat Map Analysis
6.4. Company Profiles
6.4.1. Thermo Fisher Scientific, Inc.
6.4.1.1. Participant’s Overview
6.4.1.2. Financial Performance
6.4.1.3. Product Benchmarking
6.4.1.4. Recent Developments/ Strategic Initiatives
6.4.2. STEMCELL Technologies
6.4.2.1. Participant’s Overview
6.4.2.2. Financial Performance
6.4.2.3. Product Benchmarking
6.4.2.4. Recent Developments/ Strategic Initiatives
6.4.3. Merck KGaA
6.4.3.1. Participant’s Overview
6.4.3.2. Financial Performance
6.4.3.3. Product Benchmarking
6.4.3.4. Recent Developments/ Strategic Initiatives
6.4.4. CellGenix GmbH
6.4.4.1. Participant’s Overview
6.4.4.2. Financial Performance
6.4.4.3. Product Benchmarking
6.4.4.4. Recent Developments/ Strategic Initiatives
6.4.5. PromoCell GmbH
6.4.5.1. Participant’s Overview
6.4.5.2. Financial Performance
6.4.5.3. Product Benchmarking
6.4.5.4. Recent Developments/ Strategic Initiatives
6.4.6. Takara Bio
6.4.6.1. Participant’s Overview
6.4.6.2. Financial Performance
6.4.6.3. Product Benchmarking
6.4.6.4. Recent Developments/ Strategic Initiatives
6.4.7. Lonza
6.4.7.1. Participant’s Overview
6.4.7.2. Financial Performance
6.4.7.3. Product Benchmarking
6.4.7.4. Recent Developments/ Strategic Initiatives
6.4.8. Cellartis AB
6.4.8.1. Participant’s Overview
6.4.8.2. Financial Performance
6.4.8.3. Product Benchmarking
6.4.8.4. Recent Developments/ Strategic Initiatives
6.4.9. ATCC
6.4.9.1. Participant’s Overview
6.4.9.2. Financial Performance
6.4.9.3. Product Benchmarking
6.4.9.4. Recent Developments/ Strategic Initiatives
6.4.10. AcceGen
6.4.10.1. Participant’s Overview
6.4.10.2. Financial Performance
6.4.10.3. Product Benchmarking
6.4.10.4. Recent Developments/ Strategic Initiatives
6.4.11. Cell Applications, Inc.
6.4.11.1. Participant’s Overview
6.4.11.2. Financial Performance
6.4.11.3. Product Benchmarking
6.4.11.4. Recent Developments/ Strategic Initiatives
6.4.12. Bio-Techne
6.4.12.1. Participant’s Overview
6.4.12.2. Financial Performance
6.4.12.3. Product Benchmarking
6.4.12.4. Recent Developments/ Strategic Initiatives
